CA2847589C - Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof - Google Patents

Info

Publication number

CA2847589C

CA2847589C CA2847589A CA2847589A CA2847589C CA 2847589 C CA2847589 C CA 2847589C CA 2847589 A CA2847589 A CA 2847589A CA 2847589 A CA2847589 A CA 2847589A CA 2847589 C CA2847589 C CA 2847589C

Authority

CA

Canada

Prior art keywords

sulfur

composition

tac

sodium

mice

Prior art date

2011-09-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 192
• 229910052717 sulfur Inorganic materials 0.000 title claims abstract description 136
• 239000011593 sulfur Substances 0.000 title claims abstract description 132
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title claims abstract description 86
• 238000002360 preparation method Methods 0.000 title abstract description 14
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims abstract description 129
• 229910000037 hydrogen sulfide Inorganic materials 0.000 claims abstract description 126
• 230000036542 oxidative stress Effects 0.000 claims abstract description 40
• 230000036541 health Effects 0.000 claims abstract description 15
• 239000003795 chemical substances by application Substances 0.000 claims description 46
• 239000003814 drug Substances 0.000 claims description 45
• 229940079593 drug Drugs 0.000 claims description 42
• JLQNHALFVCURHW-UHFFFAOYSA-N cyclooctasulfur Chemical compound S1SSSSSSS1 JLQNHALFVCURHW-UHFFFAOYSA-N 0.000 claims description 35
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 26
• 239000011734 sodium Substances 0.000 claims description 17
• 229910052708 sodium Inorganic materials 0.000 claims description 17
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
• 239000002253 acid Substances 0.000 claims description 12
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 12
• 235000019345 sodium thiosulphate Nutrition 0.000 claims description 12
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 11
• 229910052938 sodium sulfate Inorganic materials 0.000 claims description 11
• 235000011152 sodium sulphate Nutrition 0.000 claims description 11
• 230000000975 bioactive effect Effects 0.000 claims description 10
• 239000002775 capsule Substances 0.000 claims description 10
• 235000015872 dietary supplement Nutrition 0.000 claims description 10
• 238000011200 topical administration Methods 0.000 claims description 10
• 230000000699 topical effect Effects 0.000 claims description 9
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
• 229940124599 anti-inflammatory drug Drugs 0.000 claims description 8
• 229910052791 calcium Inorganic materials 0.000 claims description 8
• 239000011575 calcium Substances 0.000 claims description 8
• 238000007911 parenteral administration Methods 0.000 claims description 8
• 229910052700 potassium Inorganic materials 0.000 claims description 8
• 239000011591 potassium Substances 0.000 claims description 8
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 7
• 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 7
• 235000011130 ammonium sulphate Nutrition 0.000 claims description 7
• XYXNTHIYBIDHGM-UHFFFAOYSA-N ammonium thiosulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=S XYXNTHIYBIDHGM-UHFFFAOYSA-N 0.000 claims description 7
• FAYYUXPSKDFLEC-UHFFFAOYSA-L calcium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Ca+2].[O-]S([O-])(=O)=S FAYYUXPSKDFLEC-UHFFFAOYSA-L 0.000 claims description 7
• FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 claims description 7
• OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 7
• 229910052939 potassium sulfate Inorganic materials 0.000 claims description 7
• 235000011151 potassium sulphates Nutrition 0.000 claims description 7
• 230000002555 anti-neurodegenerative effect Effects 0.000 claims description 6
• 150000007513 acids Chemical class 0.000 claims description 5
• 230000001093 anti-cancer Effects 0.000 claims description 4
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
• 230000001028 anti-proliverative effect Effects 0.000 claims description 3
• 238000000034 method Methods 0.000 abstract description 71
• 229940002612 prodrug Drugs 0.000 abstract description 29
• 239000000651 prodrug Substances 0.000 abstract description 29
• 230000001575 pathological effect Effects 0.000 abstract description 16
• 239000000729 antidote Substances 0.000 abstract description 5
• 235000013305 food Nutrition 0.000 abstract description 5
• 229940075522 antidotes Drugs 0.000 abstract description 3
• 230000001737 promoting effect Effects 0.000 abstract description 2
• 241000699670 Mus sp. Species 0.000 description 99
• 238000011282 treatment Methods 0.000 description 79
• 210000002216 heart Anatomy 0.000 description 59
• 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 55
• 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 55
• 239000003981 vehicle Substances 0.000 description 49
• 206010028980 Neoplasm Diseases 0.000 description 47
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 42
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
• 230000000747 cardiac effect Effects 0.000 description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
• 230000001965 increasing effect Effects 0.000 description 34
• 206010019280 Heart failures Diseases 0.000 description 33
• 239000000243 solution Substances 0.000 description 31
• 239000000126 substance Substances 0.000 description 31
• 239000003963 antioxidant agent Substances 0.000 description 29
• 235000006708 antioxidants Nutrition 0.000 description 26
• 201000010099 disease Diseases 0.000 description 26
• 230000014509 gene expression Effects 0.000 description 26
• GWZOLWLJEJRQMZ-UHFFFAOYSA-N [S].S Chemical class [S].S GWZOLWLJEJRQMZ-UHFFFAOYSA-N 0.000 description 25
• 230000004064 dysfunction Effects 0.000 description 25
• 206010012601 diabetes mellitus Diseases 0.000 description 22
• 230000000694 effects Effects 0.000 description 21
• 229940068196 placebo Drugs 0.000 description 21
• 239000000902 placebo Substances 0.000 description 21
• HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 21
• 208000006029 Cardiomegaly Diseases 0.000 description 20
• 230000003078 antioxidant effect Effects 0.000 description 20
• -1 e.g. Proteins 0.000 description 20
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
• 238000002560 therapeutic procedure Methods 0.000 description 19
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 18
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 18
• 201000011510 cancer Diseases 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 18
• 208000015122 neurodegenerative disease Diseases 0.000 description 18
• 210000004027 cell Anatomy 0.000 description 17
• 230000001976 improved effect Effects 0.000 description 17
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 16
• 108091008611 Protein Kinase B Proteins 0.000 description 16
• 239000007903 gelatin capsule Substances 0.000 description 16
• 230000004770 neurodegeneration Effects 0.000 description 16
• 230000001225 therapeutic effect Effects 0.000 description 16
• QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 206010019233 Headaches Diseases 0.000 description 15
• 210000004369 blood Anatomy 0.000 description 15
• 239000008280 blood Substances 0.000 description 15
• 231100000869 headache Toxicity 0.000 description 15
• 230000002107 myocardial effect Effects 0.000 description 15
• 239000003642 reactive oxygen metabolite Substances 0.000 description 15
• 238000011269 treatment regimen Methods 0.000 description 15
• 208000030507 AIDS Diseases 0.000 description 14
• 230000006872 improvement Effects 0.000 description 14
• 208000027866 inflammatory disease Diseases 0.000 description 14
• 239000000523 sample Substances 0.000 description 14
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 13
• 238000002512 chemotherapy Methods 0.000 description 13
• 150000001875 compounds Chemical class 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 201000001881 impotence Diseases 0.000 description 13
• 238000003756 stirring Methods 0.000 description 13
• 208000024891 symptom Diseases 0.000 description 13
• 108010073644 Cystathionine beta-synthase Proteins 0.000 description 12
• 208000010228 Erectile Dysfunction Diseases 0.000 description 12
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
• 230000004913 activation Effects 0.000 description 12
• 235000018417 cysteine Nutrition 0.000 description 12
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 12
• 235000005911 diet Nutrition 0.000 description 12
• 230000037213 diet Effects 0.000 description 12
• 239000012153 distilled water Substances 0.000 description 12
• 230000013632 homeostatic process Effects 0.000 description 12
• 230000037361 pathway Effects 0.000 description 12
• 239000008194 pharmaceutical composition Substances 0.000 description 12
• 108090000623 proteins and genes Proteins 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• 206010016654 Fibrosis Diseases 0.000 description 11
• 206010041349 Somnolence Diseases 0.000 description 11
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 11
• 230000007423 decrease Effects 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 10
• 102100034976 Cystathionine beta-synthase Human genes 0.000 description 10
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 206010047700 Vomiting Diseases 0.000 description 10
• 238000010217 densitometric analysis Methods 0.000 description 10
• 229960003180 glutathione Drugs 0.000 description 10
• 238000003119 immunoblot Methods 0.000 description 10
• 230000002438 mitochondrial effect Effects 0.000 description 10
• 230000004899 motility Effects 0.000 description 10
• 230000000069 prophylactic effect Effects 0.000 description 10
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
• 238000001356 surgical procedure Methods 0.000 description 10
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
• 230000008673 vomiting Effects 0.000 description 10
• PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 9
• 208000032928 Dyslipidaemia Diseases 0.000 description 9
• 208000017170 Lipid metabolism disease Diseases 0.000 description 9
• 208000032140 Sleepiness Diseases 0.000 description 9
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 9
• 239000013543 active substance Substances 0.000 description 9
• 239000006071 cream Substances 0.000 description 9
• 230000002526 effect on cardiovascular system Effects 0.000 description 9
• 230000004761 fibrosis Effects 0.000 description 9
• 208000026278 immune system disease Diseases 0.000 description 9
• 230000007246 mechanism Effects 0.000 description 9
• 230000036407 pain Effects 0.000 description 9
• 229920003023 plastic Polymers 0.000 description 9
• 239000004033 plastic Substances 0.000 description 9
• 102000004169 proteins and genes Human genes 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 125000004434 sulfur atom Chemical group 0.000 description 9
• UXDMWYANCHMSJX-UHFFFAOYSA-N (benzyltrisulfanyl)methylbenzene Chemical compound C=1C=CC=CC=1CSSSCC1=CC=CC=C1 UXDMWYANCHMSJX-UHFFFAOYSA-N 0.000 description 8
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 8
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 8
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 8
• 108010024636 Glutathione Proteins 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 8
• 102000004070 NADPH Oxidase 4 Human genes 0.000 description 8
• 108010082699 NADPH Oxidase 4 Proteins 0.000 description 8
• 208000002193 Pain Diseases 0.000 description 8
• 208000007542 Paresis Diseases 0.000 description 8
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 230000001684 chronic effect Effects 0.000 description 8
• 230000003247 decreasing effect Effects 0.000 description 8
• PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 206010019465 hemiparesis Diseases 0.000 description 8
• 230000004054 inflammatory process Effects 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 8
• 230000003647 oxidation Effects 0.000 description 8
• 238000007254 oxidation reaction Methods 0.000 description 8
• 230000000241 respiratory effect Effects 0.000 description 8
• 235000021283 resveratrol Nutrition 0.000 description 8
• 229940016667 resveratrol Drugs 0.000 description 8
• 238000009612 semen analysis Methods 0.000 description 8
• 235000002639 sodium chloride Nutrition 0.000 description 8
• 230000002861 ventricular Effects 0.000 description 8
• 206010020880 Hypertrophy Diseases 0.000 description 7
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 230000007812 deficiency Effects 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 239000006185 dispersion Substances 0.000 description 7
• 239000000386 donor Substances 0.000 description 7
• 239000012065 filter cake Substances 0.000 description 7
• 230000004217 heart function Effects 0.000 description 7
• 208000003906 hydrocephalus Diseases 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 230000007170 pathology Effects 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 235000018102 proteins Nutrition 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000004202 respiratory function Effects 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 210000002303 tibia Anatomy 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
• 101100433501 Arabidopsis thaliana ACS6 gene Proteins 0.000 description 6
• 101710169171 Cysteine-rich secretory protein Proteins 0.000 description 6
• 101710195240 Cysteine-rich venom protein Proteins 0.000 description 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 206010020772 Hypertension Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000002411 adverse Effects 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 238000002592 echocardiography Methods 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 210000003414 extremity Anatomy 0.000 description 6
• 239000007789 gas Substances 0.000 description 6
• 230000003463 hyperproliferative effect Effects 0.000 description 6
• 230000002757 inflammatory effect Effects 0.000 description 6
• 239000002502 liposome Substances 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 210000003470 mitochondria Anatomy 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• 230000000750 progressive effect Effects 0.000 description 6
• 238000011084 recovery Methods 0.000 description 6
• 230000029058 respiratory gaseous exchange Effects 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 6
• 238000012546 transfer Methods 0.000 description 6
• 230000003827 upregulation Effects 0.000 description 6
• 108010018924 Heme Oxygenase-1 Proteins 0.000 description 5
• 206010022998 Irritability Diseases 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 5
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 5
• 208000007660 Residual Neoplasm Diseases 0.000 description 5
• YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• 229930003427 Vitamin E Natural products 0.000 description 5
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 5
• 208000010668 atopic eczema Diseases 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 235000020940 control diet Nutrition 0.000 description 5
• 239000003246 corticosteroid Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 229960004580 glibenclamide Drugs 0.000 description 5
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 238000007914 intraventricular administration Methods 0.000 description 5
• 208000028867 ischemia Diseases 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 230000003389 potentiating effect Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 238000002271 resection Methods 0.000 description 5
• 210000000582 semen Anatomy 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 235000010265 sodium sulphite Nutrition 0.000 description 5
• 230000019100 sperm motility Effects 0.000 description 5
• 239000010935 stainless steel Substances 0.000 description 5
• 229910001220 stainless steel Inorganic materials 0.000 description 5
• 230000009469 supplementation Effects 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 229960003080 taurine Drugs 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 229940088594 vitamin Drugs 0.000 description 5
• 229930003231 vitamin Natural products 0.000 description 5
• 235000013343 vitamin Nutrition 0.000 description 5
• 239000011782 vitamin Substances 0.000 description 5
• 235000019165 vitamin E Nutrition 0.000 description 5
• 229940046009 vitamin E Drugs 0.000 description 5
• 239000011709 vitamin E Substances 0.000 description 5
• 239000011701 zinc Substances 0.000 description 5
• 229910052725 zinc Inorganic materials 0.000 description 5
• 235000016804 zinc Nutrition 0.000 description 5
• PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 208000000059 Dyspnea Diseases 0.000 description 4
• 206010013975 Dyspnoeas Diseases 0.000 description 4
• 206010014967 Ependymoma Diseases 0.000 description 4
• 206010022773 Intracranial pressure increased Diseases 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 102000004722 NADPH Oxidases Human genes 0.000 description 4
• 108010002998 NADPH Oxidases Proteins 0.000 description 4
• 229910002651 NO3 Inorganic materials 0.000 description 4
• 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 4
• 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 4
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
• 206010063837 Reperfusion injury Diseases 0.000 description 4
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 229930003268 Vitamin C Natural products 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 4
• 229940041181 antineoplastic drug Drugs 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
• 229910002091 carbon monoxide Inorganic materials 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 229960004316 cisplatin Drugs 0.000 description 4
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
• 238000001246 colloidal dispersion Methods 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• 230000001120 cytoprotective effect Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 229960005420 etoposide Drugs 0.000 description 4
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
• 230000037406 food intake Effects 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 150000002484 inorganic compounds Chemical class 0.000 description 4
• 229910010272 inorganic material Inorganic materials 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 238000002844 melting Methods 0.000 description 4
• 230000008018 melting Effects 0.000 description 4
• 229960000485 methotrexate Drugs 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 201000008968 osteosarcoma Diseases 0.000 description 4
• 239000007800 oxidant agent Substances 0.000 description 4
• 230000004792 oxidative damage Effects 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 229960005489 paracetamol Drugs 0.000 description 4
• 235000019271 petrolatum Nutrition 0.000 description 4
• 231100000614 poison Toxicity 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000004224 protection Effects 0.000 description 4
• 239000000376 reactant Substances 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 229910052711 selenium Inorganic materials 0.000 description 4
• 239000011669 selenium Substances 0.000 description 4
• 235000011649 selenium Nutrition 0.000 description 4
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical class CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
• 229940001584 sodium metabisulfite Drugs 0.000 description 4
• 235000010262 sodium metabisulphite Nutrition 0.000 description 4
• 229910052979 sodium sulfide Inorganic materials 0.000 description 4
• GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 229940032147 starch Drugs 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 235000011149 sulphuric acid Nutrition 0.000 description 4
• 230000008961 swelling Effects 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• 235000019154 vitamin C Nutrition 0.000 description 4
• 239000011718 vitamin C Substances 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• OJOLFAIGOXZBCI-UHFFFAOYSA-N 3-mercaptopyruvic acid Chemical compound OC(=O)C(=O)CS OJOLFAIGOXZBCI-UHFFFAOYSA-N 0.000 description 3
• 206010003591 Ataxia Diseases 0.000 description 3
• 229940123208 Biguanide Drugs 0.000 description 3
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 206010012438 Dermatitis atopic Diseases 0.000 description 3
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 3
• 208000003870 Drug Overdose Diseases 0.000 description 3
• 208000007465 Giant cell arteritis Diseases 0.000 description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 208000002720 Malnutrition Diseases 0.000 description 3
• 208000000172 Medulloblastoma Diseases 0.000 description 3
• 206010027458 Metastases to lung Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 206010028813 Nausea Diseases 0.000 description 3
• 206010034156 Pathological fracture Diseases 0.000 description 3
• 206010034277 Pemphigoid Diseases 0.000 description 3
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
• 206010037423 Pulmonary oedema Diseases 0.000 description 3
• 206010039710 Scleroderma Diseases 0.000 description 3
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
• 206010071051 Soft tissue mass Diseases 0.000 description 3
• 208000005250 Spontaneous Fractures Diseases 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
• 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 210000002376 aorta thoracic Anatomy 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000008365 aqueous carrier Substances 0.000 description 3
• 230000037147 athletic performance Effects 0.000 description 3
• 201000008937 atopic dermatitis Diseases 0.000 description 3
• 230000002238 attenuated effect Effects 0.000 description 3
• 150000004283 biguanides Chemical class 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 210000004413 cardiac myocyte Anatomy 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 208000029039 cyanide poisoning Diseases 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 231100000725 drug overdose Toxicity 0.000 description 3
• 229940125753 fibrate Drugs 0.000 description 3
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 210000005003 heart tissue Anatomy 0.000 description 3
• 230000036737 immune function Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 230000002779 inactivation Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 229910052500 inorganic mineral Inorganic materials 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 235000010755 mineral Nutrition 0.000 description 3
• 239000011707 mineral Substances 0.000 description 3
• 230000006540 mitochondrial respiration Effects 0.000 description 3
• 230000036651 mood Effects 0.000 description 3
• 230000008693 nausea Effects 0.000 description 3
• 235000018343 nutrient deficiency Nutrition 0.000 description 3
• 208000008634 oligospermia Diseases 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000001590 oxidative effect Effects 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 208000005987 polymyositis Diseases 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 208000005333 pulmonary edema Diseases 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 230000000306 recurrent effect Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 208000013220 shortness of breath Diseases 0.000 description 3
• 230000037321 sleepiness Effects 0.000 description 3
• 239000000779 smoke Substances 0.000 description 3
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
• 210000004872 soft tissue Anatomy 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 230000008010 sperm capacitation Effects 0.000 description 3
• 208000000995 spontaneous abortion Diseases 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000007704 transition Effects 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
• AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 2
• VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 2
• CPJAOFOWDGRJQD-NJVNFBHUSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid;(2s)-2,5-diamino-5-oxopentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 CPJAOFOWDGRJQD-NJVNFBHUSA-N 0.000 description 2
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
• PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 2
• 102100021908 3-mercaptopyruvate sulfurtransferase Human genes 0.000 description 2
• 108030003918 3-mercaptopyruvate sulfurtransferases Proteins 0.000 description 2
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 206010000234 Abortion spontaneous Diseases 0.000 description 2
• 208000002874 Acne Vulgaris Diseases 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 208000003017 Aortic Valve Stenosis Diseases 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 206010067162 Asthenospermia Diseases 0.000 description 2
• 208000007799 Asthenozoospermia Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 208000004434 Calcinosis Diseases 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 208000002177 Cataract Diseases 0.000 description 2
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
• 206010008479 Chest Pain Diseases 0.000 description 2
• 108010077544 Chromatin Proteins 0.000 description 2
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
• 206010008909 Chronic Hepatitis Diseases 0.000 description 2
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 201000006306 Cor pulmonale Diseases 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 206010015150 Erythema Diseases 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 208000001914 Fragile X syndrome Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000002737 Heme Oxygenase-1 Human genes 0.000 description 2
• 102100028006 Heme oxygenase 1 Human genes 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 206010019799 Hepatitis viral Diseases 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 208000005615 Interstitial Cystitis Diseases 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
• 239000004201 L-cysteine Substances 0.000 description 2
• 235000013878 L-cysteine Nutrition 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 239000002841 Lewis acid Substances 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 206010050183 Macrocephaly Diseases 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 208000007466 Male Infertility Diseases 0.000 description 2
• 240000003183 Manihot esculenta Species 0.000 description 2
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 208000005767 Megalencephaly Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical group [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
• 208000009525 Myocarditis Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
• RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 208000005141 Otitis Diseases 0.000 description 2
• 206010033296 Overdoses Diseases 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• 108090000854 Oxidoreductases Proteins 0.000 description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
• 206010038063 Rectal haemorrhage Diseases 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 241001303601 Rosacea Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• 231100000182 Sperm DNA damage Toxicity 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 229960000571 acetazolamide Drugs 0.000 description 2
• BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
• 229960001009 acetylcarnitine Drugs 0.000 description 2
• 206010000496 acne Diseases 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 238000007605 air drying Methods 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• 229940056585 ammonium laurate Drugs 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940127003 anti-diabetic drug Drugs 0.000 description 2
• 230000002236 anti-hypertrophic effect Effects 0.000 description 2
• 230000002785 anti-thrombosis Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000003529 anticholesteremic agent Substances 0.000 description 2
• 229940127226 anticholesterol agent Drugs 0.000 description 2
• 239000003472 antidiabetic agent Substances 0.000 description 2
• 229940127218 antiplatelet drug Drugs 0.000 description 2
• 206010002906 aortic stenosis Diseases 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000012062 aqueous buffer Substances 0.000 description 2
• 150000007515 arrhenius acids Chemical class 0.000 description 2
• 206010003119 arrhythmia Diseases 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 230000008335 axon cargo transport Effects 0.000 description 2
• 229960002756 azacitidine Drugs 0.000 description 2
• VJCJAQSLASCYAW-UHFFFAOYSA-N azane;dodecanoic acid Chemical compound [NH4+].CCCCCCCCCCCC([O-])=O VJCJAQSLASCYAW-UHFFFAOYSA-N 0.000 description 2
• 206010003883 azoospermia Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 230000036621 balding Effects 0.000 description 2
• 239000003613 bile acid Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 150000007516 brønsted-lowry acids Chemical class 0.000 description 2
• 230000002308 calcification Effects 0.000 description 2
• LVGQIQHJMRUCRM-UHFFFAOYSA-L calcium bisulfite Chemical compound [Ca+2].OS([O-])=O.OS([O-])=O LVGQIQHJMRUCRM-UHFFFAOYSA-L 0.000 description 2
• 239000001110 calcium chloride Substances 0.000 description 2
• 229910001628 calcium chloride Inorganic materials 0.000 description 2
• 235000011148 calcium chloride Nutrition 0.000 description 2
• 235000010260 calcium hydrogen sulphite Nutrition 0.000 description 2
• 230000009787 cardiac fibrosis Effects 0.000 description 2
• 230000005961 cardioprotection Effects 0.000 description 2
• 230000003293 cardioprotective effect Effects 0.000 description 2
• 229960004203 carnitine Drugs 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• VDTNKXSVUGXUOJ-UHFFFAOYSA-N chembl2441358 Chemical compound NC(=S)C1=CC=C(O)C=C1 VDTNKXSVUGXUOJ-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000003483 chromatin Anatomy 0.000 description 2
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 229960002436 cladribine Drugs 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 230000009091 contractile dysfunction Effects 0.000 description 2
• 230000036757 core body temperature Effects 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000001934 delay Effects 0.000 description 2
• 238000001784 detoxification Methods 0.000 description 2
• UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 230000003205 diastolic effect Effects 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 208000019258 ear infection Diseases 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 206010014665 endocarditis Diseases 0.000 description 2
• 230000008694 endothelial dysfunction Effects 0.000 description 2
• 230000001973 epigenetic effect Effects 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 102000005525 fibrillarin Human genes 0.000 description 2
• 108020002231 fibrillarin Proteins 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 206010016766 flatulence Diseases 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 239000011724 folic acid Substances 0.000 description 2
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 208000024963 hair loss Diseases 0.000 description 2
• 230000003676 hair loss Effects 0.000 description 2
• 208000018578 heart valve disease Diseases 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 231100000234 hepatic damage Toxicity 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 208000015210 hypertensive heart disease Diseases 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 208000021267 infertility disease Diseases 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 150000007517 lewis acids Chemical class 0.000 description 2
• AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
• 230000008818 liver damage Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 235000001055 magnesium Nutrition 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 230000004065 mitochondrial dysfunction Effects 0.000 description 2
• 230000004898 mitochondrial function Effects 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 229910052750 molybdenum Inorganic materials 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 230000005914 myocardial expression Effects 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 231100000417 nephrotoxicity Toxicity 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 150000002825 nitriles Chemical class 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
• 229960002340 pentostatin Drugs 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 239000002574 poison Substances 0.000 description 2
• 230000007096 poisonous effect Effects 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 2
• 229940099427 potassium bisulfite Drugs 0.000 description 2
• 239000001103 potassium chloride Substances 0.000 description 2
• 235000011164 potassium chloride Nutrition 0.000 description 2
• 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 2
• MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 238000004321 preservation Methods 0.000 description 2
• 230000000861 pro-apoptotic effect Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000005522 programmed cell death Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 201000004700 rosacea Diseases 0.000 description 2
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
• 201000000980 schizophrenia Diseases 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 229940091258 selenium supplement Drugs 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 208000007056 sickle cell anemia Diseases 0.000 description 2
• DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
• 229960002639 sildenafil citrate Drugs 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 239000002002 slurry Substances 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 229940080263 sodium dichloroacetate Drugs 0.000 description 2
• 229940045870 sodium palmitate Drugs 0.000 description 2
• LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 2
• GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 230000021595 spermatogenesis Effects 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 238000004659 sterilization and disinfection Methods 0.000 description 2
• 208000023516 stroke disease Diseases 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 229940006280 thiosulfate ion Drugs 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 201000004647 tinea pedis Diseases 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 210000000689 upper leg Anatomy 0.000 description 2
• 208000011479 upper respiratory tract disease Diseases 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 229940099259 vaseline Drugs 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 201000001862 viral hepatitis Diseases 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
• TWUSDDMONZULSC-HZMBPMFUSA-N (1r,2s)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• GADIJPCDIWZEMB-BTNVMJJCSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O GADIJPCDIWZEMB-BTNVMJJCSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• XTBQNQMNFXNGLR-MKSBGGEFSA-N (2s)-1-(2-ethylphenoxy)-3-[[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propan-2-ol;oxalic acid Chemical compound OC(=O)C(O)=O.CCC1=CC=CC=C1OC[C@@H](O)CN[C@@H]1C2=CC=CC=C2CCC1 XTBQNQMNFXNGLR-MKSBGGEFSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• YCNMAPLPQYQJFC-UHFFFAOYSA-N (4-carbamothioylphenyl) 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C)C(=O)OC1=CC=C(C(N)=S)C=C1 YCNMAPLPQYQJFC-UHFFFAOYSA-N 0.000 description 1
• YZMHNNLDUWRZFW-UHFFFAOYSA-N (4-methoxyphenyl)-morpholin-4-yl-sulfanyl-sulfanylidene-$l^{5}-phosphane;morpholine Chemical compound C1COCC[NH2+]1.C1=CC(OC)=CC=C1P([S-])(=S)N1CCOCC1 YZMHNNLDUWRZFW-UHFFFAOYSA-N 0.000 description 1
• UDIODXADSSQKTM-GUHNCMMLSA-N (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5- Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 UDIODXADSSQKTM-GUHNCMMLSA-N 0.000 description 1
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
• PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
• ULXKXLZEOGLCRJ-UHFFFAOYSA-N 2-azaniumyl-3-ethylsulfanylpropanoate Chemical compound CCSCC(N)C(O)=O ULXKXLZEOGLCRJ-UHFFFAOYSA-N 0.000 description 1
• JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
• VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 1
• 239000010963 304 stainless steel Substances 0.000 description 1
• LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 description 1
• PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
• 230000002407 ATP formation Effects 0.000 description 1
• 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 208000002485 Adiposis dolorosa Diseases 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 240000006054 Agastache cana Species 0.000 description 1
• 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
• 102100036826 Aldehyde oxidase Human genes 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102100026882 Alpha-synuclein Human genes 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 206010002023 Amyloidoses Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 208000001839 Antisynthetase syndrome Diseases 0.000 description 1
• 241000086254 Arnica montana Species 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
• 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
• 201000002827 Balo concentric sclerosis Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 208000009766 Blau syndrome Diseases 0.000 description 1
• 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
• 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
• 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
• 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 101000929923 Caenorhabditis elegans Acetylcholinesterase 1 Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
• 208000010007 Cogan syndrome Diseases 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010252 Concentric sclerosis Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• 244000163122 Curcuma domestica Species 0.000 description 1
• 235000003392 Curcuma domestica Nutrition 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 101710126127 Cysteine-rich secretory protein 2 Proteins 0.000 description 1
• 102100027350 Cysteine-rich secretory protein 2 Human genes 0.000 description 1
• 206010068271 Cystic fibrosis related diabetes Diseases 0.000 description 1
• 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 230000028937 DNA protection Effects 0.000 description 1
• 231100001074 DNA strand break Toxicity 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 241001633942 Dais Species 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 206010012444 Dermatitis diaper Diseases 0.000 description 1
• 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 208000008960 Diabetic foot Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 208000003105 Diaper Rash Diseases 0.000 description 1
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• 208000021866 Dressler syndrome Diseases 0.000 description 1
• 208000005171 Dysmenorrhea Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102400001047 Endostatin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010014968 Ependymoma malignant Diseases 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 208000004332 Evans syndrome Diseases 0.000 description 1
• 239000001653 FEMA 3120 Substances 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
• 206010056696 Gaze palsy Diseases 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 241000207963 Harpagophytum Species 0.000 description 1
• 208000016905 Hashimoto encephalopathy Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 206010019939 Herpes gestationis Diseases 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
• 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 208000029470 Hughes-Stovin syndrome Diseases 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
• 244000141009 Hypericum perforatum Species 0.000 description 1
• 235000017309 Hypericum perforatum Nutrition 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• 239000004158 L-cystine Substances 0.000 description 1
• 235000019393 L-cystine Nutrition 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 206010024434 Lichen sclerosus Diseases 0.000 description 1
• 208000012309 Linear IgA disease Diseases 0.000 description 1
• 208000035752 Live birth Diseases 0.000 description 1
• 208000000185 Localized scleroderma Diseases 0.000 description 1
• 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
• JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
• TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
• 208000009777 Majeed syndrome Diseases 0.000 description 1
• 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
• 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
• 241000220225 Malus Species 0.000 description 1
• 235000011430 Malus pumila Nutrition 0.000 description 1
• 235000015103 Malus silvestris Nutrition 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• SMNOERSLNYGGOU-UHFFFAOYSA-N Mefruside Chemical compound C=1C=C(Cl)C(S(N)(=O)=O)=CC=1S(=O)(=O)N(C)CC1(C)CCCO1 SMNOERSLNYGGOU-UHFFFAOYSA-N 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 208000037093 Menstruation Disturbances Diseases 0.000 description 1
• 206010027339 Menstruation irregular Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 206010027603 Migraine headaches Diseases 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 206010027982 Morphoea Diseases 0.000 description 1
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 206010028424 Myasthenic syndrome Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010029229 Neuralgic amyotrophy Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
• 206010068319 Oropharyngeal pain Diseases 0.000 description 1
• 206010031123 Orthopnoea Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 208000025174 PANDAS Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 201000010183 Papilledema Diseases 0.000 description 1
• 206010033712 Papilloedema Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
• 208000004788 Pars Planitis Diseases 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 206010061336 Pelvic neoplasm Diseases 0.000 description 1
• 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 235000016787 Piper methysticum Nutrition 0.000 description 1
• 240000005546 Piper methysticum Species 0.000 description 1
• KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
• 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
• 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 206010036772 Proctalgia Diseases 0.000 description 1
• 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 244000018633 Prunus armeniaca Species 0.000 description 1
• 235000009827 Prunus armeniaca Nutrition 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
• 229910000589 SAE 304 stainless steel Inorganic materials 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
• 102100037599 SPARC Human genes 0.000 description 1
• 241000124033 Salix Species 0.000 description 1
• 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 241000287219 Serinus canaria Species 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
• 208000031849 Squamous cell carcinoma of the anal canal Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 206010042276 Subacute endocarditis Diseases 0.000 description 1
• HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
• 108700025695 Suppressor Genes Proteins 0.000 description 1
• 208000000573 Supratentorial Neoplasms Diseases 0.000 description 1
• 208000002286 Susac Syndrome Diseases 0.000 description 1
• 208000010265 Sweet syndrome Diseases 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
• 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
• 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003270 Vitamin B Natural products 0.000 description 1
• 229930003451 Vitamin B1 Natural products 0.000 description 1
• 229930003316 Vitamin D Natural products 0.000 description 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
• 229930003448 Vitamin K Natural products 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000010399 Wasting Syndrome Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 102100033220 Xanthine oxidase Human genes 0.000 description 1
• 108010093894 Xanthine oxidase Proteins 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
• 235000004552 Yucca aloifolia Nutrition 0.000 description 1
• 244000116042 Yucca brevifolia Species 0.000 description 1
• 235000012044 Yucca brevifolia Nutrition 0.000 description 1
• 235000017049 Yucca glauca Nutrition 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 244000273928 Zingiber officinale Species 0.000 description 1
• 235000006886 Zingiber officinale Nutrition 0.000 description 1
• JEEWZRQQYWVJCX-WEWVERJPSA-N [4-(5-sulfanylidenedithiol-3-yl)phenyl] (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate Chemical compound C([C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC=1C=CC=CC=1)\C=C/CCCC(=O)OC(C=C1)=CC=C1C1=CC(=S)SS1 JEEWZRQQYWVJCX-WEWVERJPSA-N 0.000 description 1
• SJLZXDOBSHEDIF-UHFFFAOYSA-N [4-(5-sulfanylidenedithiol-3-yl)phenyl] 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC=2C=CC(=CC=2)C=2SSC(=S)C=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 SJLZXDOBSHEDIF-UHFFFAOYSA-N 0.000 description 1
• BRDUXOHVEZVAHI-UHFFFAOYSA-N [4-(5-sulfanylidenedithiol-3-yl)phenyl] 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1CC(=O)OC1=CC=C(C=2SSC(=S)C=2)C=C1 BRDUXOHVEZVAHI-UHFFFAOYSA-N 0.000 description 1
• UFUDJOQZWNWNDH-UHFFFAOYSA-N [S].S.S Chemical compound [S].S.S UFUDJOQZWNWNDH-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 229960002122 acebutolol Drugs 0.000 description 1
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
• 229960004176 aclarubicin Drugs 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000019269 advanced heart failure Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 235000020224 almond Nutrition 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 108090000185 alpha-Synuclein Proteins 0.000 description 1
• HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
• 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
• PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
• 229960002213 alprenolol Drugs 0.000 description 1
• 229960000711 alprostadil Drugs 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 229960002550 amrubicin Drugs 0.000 description 1
• VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 201000007564 anal canal squamous cell carcinoma Diseases 0.000 description 1
• 208000014534 anaplastic ependymoma Diseases 0.000 description 1
• 229960005238 anethole trithione Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 230000000181 anti-adherent effect Effects 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002001 anti-metastasis Effects 0.000 description 1
• 230000000733 anti-osteolytic effect Effects 0.000 description 1
• 239000003911 antiadherent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 230000006851 antioxidant defense Effects 0.000 description 1
• 229940124522 antiretrovirals Drugs 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
• 229960002594 arsenic trioxide Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• KSGSPUPKSFERSZ-ZVPRKPEASA-N atc protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 KSGSPUPKSFERSZ-ZVPRKPEASA-N 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
• 208000001974 autoimmune enteropathy Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 201000005011 autoimmune peripheral neuropathy Diseases 0.000 description 1
• 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
• 206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 1
• 208000029407 autoimmune urticaria Diseases 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 230000002886 autophagic effect Effects 0.000 description 1
• 229960000307 avanafil Drugs 0.000 description 1
• WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 1
• KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960000794 baclofen Drugs 0.000 description 1
• 229950011276 belotecan Drugs 0.000 description 1
• LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 238000011138 biotechnological process Methods 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000002168 brachiocephalic trunk Anatomy 0.000 description 1
• PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
• 229950010231 brequinar Drugs 0.000 description 1
• 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 229960004111 buformin Drugs 0.000 description 1
• XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
• 229960004064 bumetanide Drugs 0.000 description 1
• 229950009770 butaxamine Drugs 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 230000028956 calcium-mediated signaling Effects 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 230000008209 cardiovascular development Effects 0.000 description 1
• 230000009084 cardiovascular function Effects 0.000 description 1
• 230000005800 cardiovascular problem Effects 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 229960003261 carmofur Drugs 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229960001222 carteolol Drugs 0.000 description 1
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 229960002320 celiprolol Drugs 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960005110 cerivastatin Drugs 0.000 description 1
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
• YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
• NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
• 230000005465 channeling Effects 0.000 description 1
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960001523 chlortalidone Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 208000006571 choroid plexus carcinoma Diseases 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 208000013507 chronic prostatitis Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 208000024376 chronic urticaria Diseases 0.000 description 1
• 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
• 229960002174 ciprofibrate Drugs 0.000 description 1
• KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000009535 clinical urine test Methods 0.000 description 1
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
• 229960000928 clofarabine Drugs 0.000 description 1
• 229960001214 clofibrate Drugs 0.000 description 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
• 229960004070 clopamide Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 235000017471 coenzyme Q10 Nutrition 0.000 description 1
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
• 229940110767 coenzyme Q10 Drugs 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 201000003056 complement component 2 deficiency Diseases 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 208000003611 congenital autoimmune diabetes mellitus Diseases 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 238000007887 coronary angioplasty Methods 0.000 description 1
• 210000005226 corpus cavernosum Anatomy 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 238000002316 cosmetic surgery Methods 0.000 description 1
• 229960005168 croscarmellose Drugs 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 235000003373 curcuma longa Nutrition 0.000 description 1
• 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 229960003603 decitabine Drugs 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
• 229960005081 diclofenamide Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• JDXYSCUOABNLIR-UHFFFAOYSA-N diethyl 2-oxobutanedioate Chemical compound CCOC(=O)CC(=O)C(=O)OCC JDXYSCUOABNLIR-UHFFFAOYSA-N 0.000 description 1
• NGRAIMFUWGFAEM-UHFFFAOYSA-N diethyl 2-oxopentanedioate Chemical compound CCOC(=O)CCC(=O)C(=O)OCC NGRAIMFUWGFAEM-UHFFFAOYSA-N 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• VTYGSWGUBDXCRA-UHFFFAOYSA-L dipotassium;2-oxopentanedioate Chemical compound [K+].[K+].[O-]C(=O)CCC(=O)C([O-])=O VTYGSWGUBDXCRA-UHFFFAOYSA-L 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
• MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
• 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 208000001780 epistaxis Diseases 0.000 description 1
• OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
• 229950005098 ethoxzolamide Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229940031005 ethyl cysteine Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
• 229960004945 etoricoxib Drugs 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 208000002980 facial hemiatrophy Diseases 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 208000001031 fetal erythroblastosis Diseases 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 1
• 229960002524 firocoxib Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960004369 flufenamic acid Drugs 0.000 description 1
• LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• 230000003371 gabaergic effect Effects 0.000 description 1
• 229960003980 galantamine Drugs 0.000 description 1
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
• 239000010647 garlic oil Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000007897 gelcap Substances 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 208000004104 gestational diabetes Diseases 0.000 description 1
• 235000008397 ginger Nutrition 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000004536 heart mitochondria Anatomy 0.000 description 1
• 208000014617 hemorrhoid Diseases 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 241000411851 herbal medicine Species 0.000 description 1
• 235000008216 herbs Nutrition 0.000 description 1
• 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• FEXCMMPRRBSCRG-UHFFFAOYSA-N hexasulfur Chemical compound S1SSSSS1 FEXCMMPRRBSCRG-UHFFFAOYSA-N 0.000 description 1
• 208000002557 hidradenitis Diseases 0.000 description 1
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 210000002758 humerus Anatomy 0.000 description 1
• DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 229960002003 hydrochlorothiazide Drugs 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000000852 hydrogen donor Substances 0.000 description 1
• 230000005660 hydrophilic surface Effects 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 229960001195 imidapril Drugs 0.000 description 1
• KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 201000008319 inclusion body myositis Diseases 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 239000000976 ink Substances 0.000 description 1
• 239000002917 insecticide Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 210000000876 intercostal muscle Anatomy 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 229940039009 isoproterenol Drugs 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960001848 lamotrigine Drugs 0.000 description 1
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 229950005692 larotaxel Drugs 0.000 description 1
• SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
• 208000001921 latent autoimmune diabetes in adults Diseases 0.000 description 1
• 210000003140 lateral ventricle Anatomy 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 229950003488 licofelone Drugs 0.000 description 1
• UAWXGRJVZSAUSZ-UHFFFAOYSA-N licofelone Chemical compound OC(=O)CC=1N2CC(C)(C)CC2=C(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 UAWXGRJVZSAUSZ-UHFFFAOYSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 235000019136 lipoic acid Nutrition 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000027928 long-term synaptic potentiation Effects 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 235000012661 lycopene Nutrition 0.000 description 1
• 229960004999 lycopene Drugs 0.000 description 1
• OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
• 239000001751 lycopene Substances 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 229960003640 mafenide Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000003760 magnetic stirring Methods 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• 238000013227 male C57BL/6J mice Methods 0.000 description 1
• 210000005001 male reproductive tract Anatomy 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229960003464 mefenamic acid Drugs 0.000 description 1
• 229960004678 mefruside Drugs 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• YFDLHELOZYVNJE-UHFFFAOYSA-L mercury diiodide Chemical compound I[Hg]I YFDLHELOZYVNJE-UHFFFAOYSA-L 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 235000006109 methionine Nutrition 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
• 229960002817 metolazone Drugs 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 229950009116 mevastatin Drugs 0.000 description 1
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 238000001471 micro-filtration Methods 0.000 description 1
• 239000013081 microcrystal Substances 0.000 description 1
• 239000013080 microcrystalline material Substances 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 208000015994 miscarriage Diseases 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
• 210000001700 mitochondrial membrane Anatomy 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000011733 molybdenum Substances 0.000 description 1
• 208000029077 monogenic diabetes Diseases 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
• YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 229950007221 nedaplatin Drugs 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 208000008795 neuromyelitis optica Diseases 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• 229960000965 nimesulide Drugs 0.000 description 1
• HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
• 208000005346 nocturnal enuresis Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 235000021590 normal diet Nutrition 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
• 230000009965 odorless effect Effects 0.000 description 1
• 201000002663 oligoasthenoteratozoospermia Diseases 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
• 229950001094 ortataxel Drugs 0.000 description 1
• 208000012144 orthopnea Diseases 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 208000028776 osteoblastic osteosarcoma Diseases 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
• 229960004570 oxprenolol Drugs 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 201000005580 palindromic rheumatism Diseases 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
• 229960004662 parecoxib Drugs 0.000 description 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
• 230000008775 paternal effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 201000004341 pediatric supratentorial ependymoma Diseases 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 229960001476 pentoxifylline Drugs 0.000 description 1
• 229960002582 perindopril Drugs 0.000 description 1
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000003617 peroxidasic effect Effects 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 230000003094 perturbing effect Effects 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003243 phenformin Drugs 0.000 description 1
• ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 108091005981 phosphorylated proteins Proteins 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229960001221 pirarubicin Drugs 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
• 229960004403 pixantrone Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229910000057 polysulfane Inorganic materials 0.000 description 1
• 239000005077 polysulfide Substances 0.000 description 1
• 229920001021 polysulfide Polymers 0.000 description 1
• 150000008117 polysulfides Polymers 0.000 description 1
• 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
• 229960000214 pralatrexate Drugs 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 235000013406 prebiotics Nutrition 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003140 primary amides Chemical class 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 208000001282 primary progressive aphasia Diseases 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 230000000436 pro-erectile effect Effects 0.000 description 1
• 230000003244 pro-oxidative effect Effects 0.000 description 1
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
• 229960003081 probenecid Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 231100000586 procarcinogen Toxicity 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 229960005385 proguanil Drugs 0.000 description 1
• SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 239000000649 purine antagonist Substances 0.000 description 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
• 239000003790 pyrimidine antagonist Substances 0.000 description 1
• 229960001455 quinapril Drugs 0.000 description 1
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
• AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
• 229930192524 radicicol Natural products 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 239000012048 reactive intermediate Substances 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000002278 reconstructive surgery Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 239000013074 reference sample Substances 0.000 description 1
• 230000018406 regulation of metabolic process Effects 0.000 description 1
• 208000009169 relapsing polychondritis Diseases 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 230000008263 repair mechanism Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
• 229960003147 reserpine Drugs 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960004136 rivastigmine Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• 229950009213 rubitecan Drugs 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229960000953 salsalate Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
• 229960004617 sapropterin Drugs 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 230000009863 secondary prevention Effects 0.000 description 1
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 235000004400 serine Nutrition 0.000 description 1
• 206010040400 serum sickness Diseases 0.000 description 1
• 230000036299 sexual function Effects 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000009131 signaling function Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 229960001866 silicon dioxide Drugs 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• BUBOVHRAKJTFKI-UHFFFAOYSA-M sodium;4-hydroxy-2,4-dioxobutanoate Chemical compound [Na+].OC(=O)C(=O)CC([O-])=O BUBOVHRAKJTFKI-UHFFFAOYSA-M 0.000 description 1
• 239000002047 solid lipid nanoparticle Substances 0.000 description 1
• 239000002594 sorbent Substances 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 229960002920 sorbitol Drugs 0.000 description 1
• 229960002370 sotalol Drugs 0.000 description 1
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 208000002254 stillbirth Diseases 0.000 description 1
• 231100000537 stillbirth Toxicity 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229960005404 sulfamethoxazole Drugs 0.000 description 1
• 229960005559 sulforaphane Drugs 0.000 description 1
• 235000015487 sulforaphane Nutrition 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
• 229960002573 sultiame Drugs 0.000 description 1
• KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
• 229960003708 sumatriptan Drugs 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 208000015033 supratentorial ependymoma Diseases 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000007939 sustained release tablet Substances 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 229960000835 tadalafil Drugs 0.000 description 1
• IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 102000013498 tau Proteins Human genes 0.000 description 1
• 108010026424 tau Proteins Proteins 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960002871 tenoxicam Drugs 0.000 description 1
• WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
• MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
• 229950009016 tesetaxel Drugs 0.000 description 1
• 229960005333 tetrabenazine Drugs 0.000 description 1
• 230000000542 thalamic effect Effects 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
• 229960002663 thioctic acid Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 1
• SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
• 229960000838 tipranavir Drugs 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
• 229960000488 tizanidine Drugs 0.000 description 1
• 229960002905 tolfenamic acid Drugs 0.000 description 1
• YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 190014017283 triplatin tetranitrate Chemical compound 0.000 description 1
• 229950002860 triplatin tetranitrate Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• KRURGYOKPVLRHQ-UHFFFAOYSA-L trithionate(2-) Chemical compound [O-]S(=O)(=O)SS([O-])(=O)=O KRURGYOKPVLRHQ-UHFFFAOYSA-L 0.000 description 1
• 235000013976 turmeric Nutrition 0.000 description 1
• 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 229960000653 valrubicin Drugs 0.000 description 1
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
• 229960000922 vinflunine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000004304 visual acuity Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 235000010374 vitamin B1 Nutrition 0.000 description 1
• 239000011691 vitamin B1 Substances 0.000 description 1
• 235000019166 vitamin D Nutrition 0.000 description 1
• 239000011710 vitamin D Substances 0.000 description 1
• 150000003710 vitamin D derivatives Chemical class 0.000 description 1
• 235000019168 vitamin K Nutrition 0.000 description 1
• 239000011712 vitamin K Substances 0.000 description 1
• 150000003721 vitamin K derivatives Chemical class 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 229940046008 vitamin d Drugs 0.000 description 1
• 229940046010 vitamin k Drugs 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 230000007279 water homeostasis Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1
• MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
• 229960000537 xipamide Drugs 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 229960000317 yohimbine Drugs 0.000 description 1
• GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
• 229960002769 zofenopril Drugs 0.000 description 1
• IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
• UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
• 229960002911 zonisamide Drugs 0.000 description 1
• 229960000641 zorubicin Drugs 0.000 description 1
• FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1